VCRE · Vicore Pharma Holding AB · Documents
Market Cap
$254.32M
Shares
28.16M
Volume · Oct 22
103.37K
Avg daily vol (3M)
21.17K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Vicore Pharma Holding AB's Phase 2b ASPIRE trial will continue without modification after passing a pre-planned futility analysis, with 52-week topline results expected in mid-2027. | 2026-10-22 | 2026-10-31 | |
| 6-K | — | 2026-09-30 | — | |
| 6-K | — | 2026-08-21 | — | |
| 6-K | — | 2026-07-06 | — |
Showing 1–4 of 4 filings